TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15531010
Drug: 8 NaP
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 NaP tablets (1.5 g NaP/tablet) each morning for 28 days (group B)
Study: 25907673
Drug: Droxidopa (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droxidopa (200 to 600 mg TID)
Study: 25907673
Drug: Droxidopa plus
Normalized name: Droxidopa
DrugBank: Droxidopa (DB06262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Droxidopa plus Carbidopa (25 or 50 mg TID)
Study: 25907673
Drug: Co-treatment (Droxidopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-treatment (Droxidopa + Carbidopa)
Study: 21173013
Drug: Anakinra (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anakinra (2 mg/kg subcutaneous daily, maximum 100 mg)
Study: 12563620
Drug: Neoral (cyclosporine)
Normalized name: cyclosporine Oral Capsule [Neoral]
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoral (cyclosporine) with olestra (0.35 g/kg, max 16 g)
Study: 10694769
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral iron supplementation (2-3 mg of elemental iron per kg of body weight) for 3 months
Study: 9181765
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment (group II)
Study: 8451344
Drug: Rational-Emotive Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rational-Emotive Therapy
Study: 8451344
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (Rational-Emotive Therapy + Auditory subliminal stimulation)
Study: 3488384
Drug: 1000 IU
Normalized name: D 1000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 IU vitamin D3 daily (group +D)
Study: 26584454
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg Careless™
Study: 26584454
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg Careless™
Study: 26584454
Drug: Careless™ (3000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Careless™ (3000 µg/mL)
Study: 26584454
Drug: Careless™ (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Careless™ (1500 µg/mL)
Study: 26584454
Drug: Careless™ (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Careless™ (300 µg/mL)
Study: 23534775
Drug: Granisetron injection
Normalized name: granisetron Injection
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Granisetron injection as primary prophylaxis
Study: 21221620
Drug: Intratympanic dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intratympanic dexamethasone injection (ITDI) - 4 sequential injections within 2 weeks after systemic steroids
Study: 21221620
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group - no further medications after systemic steroids
Study: 14664881
Drug: Arimidex (anastrozole)
Normalized name: anastrozole Oral Tablet [Arimidex]
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Arimidex (anastrozole) alone or in combination with tamoxifen
Study: 8776638
Drug: Low-dose heparin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose heparin management (100 IU/kg i.v. and 0 to 1,000 IU/L priming; target ACT over 180 seconds)
Study: 8776638
Drug: High-dose heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose heparin management (300 IU/kg i.v. and 5,000 IU/L priming; target ACT over 480 seconds)
Study: 6429872
Drug: Intravenous feeding
Normalized name: SET,FEEDING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous feeding with amino acid dextrose solutions and fat emulsions
Study: 31655622
Drug: Ambrisentan 5-10
Normalized name: ambrisentan 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambrisentan 5-10 mg/day
Study: 27163237
Drug: Dexamethasone 0.7
Normalized name: dexamethasone 0.7 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 0.7 mg
Study: 9989713
Drug: Physiotherapy Treatment
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Physiotherapy Treatment (PT)
Study: 2148341
Drug: Moclobemide (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide (300 mg daily in three divided doses)
Study: 7306966
Drug: CMF (cyclophosphamide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMF (cyclophosphamide, 400 mg/sq m; methotrexate, 30 mg/sq m; and 5‐FU, 500 mg/sq m, given i.v. every 2 weeks)
Study: 7306966
Drug: 5‐fluorouracil (5‐FU,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐fluorouracil (5‐FU, 500 mg/sq m i.v. every week)
Study: 31551226
Drug: Carvedilol combined
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carvedilol combined with conventional therapy
Study: 23701010
Drug: Oral hygiene
Normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hygiene instruction and supragingival scaling (treatment group, n = 26)
Study: 23701010
Drug: No periodontal
Approvals — FDA: no, EMA: no, PMDA: no
Description: No periodontal treatment (control group, n = 29)
Study: 21889802
Drug: Behavior or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavior or cognitive therapy (16 sessions) with fluvoxamine
Study: 21889802
Drug: Behavior or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavior or cognitive therapy (16 sessions) without fluvoxamine
Study: 18637764
Drug: P. ginseng
Approvals — FDA: no, EMA: no, PMDA: no
Description: P. ginseng and warfarin (n = 12)
Study: 18637764
Drug: Warfarin only
Normalized name: Warfarin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin only (n = 13)
Study: 10095815
Drug: Mid-morning snack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mid-morning snack served 2 hours after insulin injection
Study: 18294568
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy (secondary prevention)
Study: 18294568
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy (new-onset or postoperative AF)
Study: 6536513
Drug: Cimetidine (Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (Group III: 5 mg kg‐1 orally in a.m.)
Study: 6536513
Drug: Cimetidine (Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (Group IV: 5 mg kg‐1 orally in a.m. and glycopyrrolate 5 micrograms kg‐1 in a.m.)
Study: 6536513
Drug: Cimetidine (Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (Group V: 5 mg kg‐1 orally h.s. and a.m.)
Study: 25248854
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care presentation encouraging employers to work with their health plan to improve depression treatment quality indicators
Study: 22752636
Drug: GFD +
Normalized name: Gluten-free diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: GFD + prednisolone (1 mg/kg for 4 weeks, n = 16)
Study: 22752636
Drug: GFD +
Normalized name: Gluten-free diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: GFD + prednisolone (1 mg/kg for 4 weeks)
Study: 7150496
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of fenoterol aerosol (400 micrograms)
Study: 7150496
Drug: Buccal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Buccal administration of fenoterol (400 micrograms)
Study: 27871538
Drug: Dexmedetomidine 1‐μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 1‐μg/kg load followed by 1‐μg/(kg h) infusion
Study: 27871538
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion at 300 μg/(kg min) reduced to 250‐μg/(kg min) infusion
Study: 24291194
Drug: HOWARU(®) Restore
Normalized name: Restone
Approvals — FDA: no, EMA: no, PMDA: no
Description: HOWARU(®) Restore probiotic 1.70×10(10) CFU (high-dose, n=168)
Study: 24291194
Drug: HOWARU(®) Restore
Normalized name: Restone
Approvals — FDA: no, EMA: no, PMDA: no
Description: HOWARU(®) Restore probiotic 4.17×10(9) CFU (low-dose, n=168)
Study: 12046068
Drug: Preoperative regional
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative regional artery chemotherapy (PRACT)
Study: 10459075
Drug: Preoperative oral
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative oral carbohydrate administration (CHO-H)
Study: 10459075
Drug: Preoperative oral
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative oral carbohydrate administration (CHO-C)
Study: 7608279
Drug: L-Arginine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-Arginine infusion (500 mg/kg over 30 min)
Study: 2193166
Drug: Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate (800 mg per day)
Study: 499288
Drug: Oral aminophylline
Normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral aminophylline 500 mg
Study: 499288
Drug: Aminophylline suppository
Normalized name: aminophylline Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline suppository 500 mg
Study: 30999952
Drug: SMS text
Normalized name: Samarium Sm-153
DrugBank: Samarium Sm-153 (DB12905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SMS text message intervention plus Treatment As Usual (TAU) receiving nine SMS text messages at 1, 2, 3, 4, 5, 6, 8, 10 and 12 months post-discharge.
Study: 30999952
Drug: Treatment As
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment As Usual (TAU) alone.
Study: 27917593
Drug: Pharmacological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological treatment 1
Study: 27917593
Drug: Pharmacological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological treatment 2
Study: 25935596
Drug: Methylaminolevulinate photodynamic
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylaminolevulinate photodynamic therapy (MAL-PDT)
Study: 25935596
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (tumors without treatment failure)
Study: 20881878
Drug: Creatine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine (5 g·d)
Study: 19563393
Drug: Ezetimibe 10
Normalized name: ezetimibe 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe 10 mg and Simvastatin 10 mg daily (E10/S10)
Study: 16452264
Drug: Operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Operative treatment of medial collateral ligament injury (n = 23)
Study: 16452264
Drug: Nonoperative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonoperative treatment of medial collateral ligament injury (n = 24)
Study: 8972892
Drug: Captopril (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (12.5 to 50 mg twice daily)
Study: 8972892
Drug: Beta-blockers (atenolol:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blockers (atenolol: 25 to 100 mg once daily or propranolol: 10 to 80 mg twice daily)
Study: 26861976
Drug: EMLA topical
Normalized name: EMLA Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: EMLA topical anaesthetic (2.5% lidocaine and 2.5% prilocaine)
Study: 26861976
Drug: Ametop topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ametop topical anaesthetic (4% tetracaine)
Study: 24379278
Drug: Diuretic efficiency
Normalized name: hydralazine hydrochloride / hydrochlorothiazide / reserpine Oral Tablet [Diuretic Ap-Es]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretic efficiency (DE) estimated as net fluid output produced per 40 mg of furosemide equivalents, dichotomized into high versus low DE.
Study: 24379278
Drug: Traditional baseline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional baseline characteristics and metrics of renal function and preadmission diuretic therapy.
Study: 22679721
Drug: Huzhang Tongfeng
Approvals — FDA: no, EMA: no, PMDA: no
Description: Huzhang Tongfeng Granule (HTG), diclofenac sodium extended‐release capsule, Jinhuang Ointment (JO) in the acute stage; Yinlian Tongfeng Granule (YTG) and Benzbromarone Tablet (BT) in the intermission stage.
Study: 22679721
Drug: diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: diclofenac sodium extended‐release capsule in the acute stage; Benzbromarone Tablet (BT) in the intermission stage.
Study: 2403484
Drug: All three
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: All three antibiotics (TCV)
Study: 31830292
Drug: Topical citicoline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical citicoline eye drops three times a day for 1 month
Study: 11430565
Drug: Prednisolone (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (5 mg at 09:00 and 2.5 mg at 14:00)
Study: 11430565
Drug: Dexamethasone (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (0.5 mg at 23:00) with prednisolone (2.5 mg at 14:00)
Study: 9409140
Drug: 3 months
Normalized name: TABLET, DOSE PACK, 3 MONTHS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 months outpatient treatment (experimental group)
Study: 9409140
Drug: 6 months
Normalized name: leuprolide 45 mg/6 months intramuscular kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 months outpatient treatment (experimental group)
Study: 9409140
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (3 months treatment)
Study: 9409140
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (6 months treatment)
Study: 7968645
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose oral contraceptive (30 mcg ethinyl estradiol plus 75 mcg gestodene)
Study: 30277890
Drug: Sedation, vasoactive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sedation, vasoactive medications, or occurrence of pneumothorax
Study: 28350519
Drug: Other treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other treatments (MISC)
Study: 26184525
Drug: Rilonacept (160mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rilonacept (160mg intrabursal injection)
Study: 21992986
Drug: Expedited Partner
Normalized name: Milkthistle Fruit (Silybum Marianum L. Gaertner)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Expedited Partner Therapy (EPT)
Study: 17004900
Drug: Soy protein
Normalized name: Soy Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy protein (25 g protein, four times a week for 4 weeks)
Study: 14581272
Drug: Docetaxel (36
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (36 mg/m²)
Study: 14581272
Drug: Paclitaxel (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (80 mg/m²)
Study: 8702052
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 150 mg kg‐1 in 250 ml 5% dextrose i.v. over 30 min
Study: 8702052
Drug: Placebo in
Normalized name: placebo INTRAVEN VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in 250 ml 5% dextrose i.v. over 30 min
Study: 1731546
Drug: 2% lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% lidocaine (100 mg IV) followed 1 min later by propofol (2 mg/kg)
Study: 1731546
Drug: Propofol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (2 mg/kg IV)
Study: 1731546
Drug: 2% lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% lidocaine administered after a tourniquet inflated to 50 mm Hg for 1 min
Study: 6748177
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of zinc sulfate daily for eight weeks
Study: 26278425
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg rosuvastatin daily from preoperative day 7 to postoperative day 28
Study: 23616503
Drug: Whole-grain (WG)
Normalized name: rice (whole grain) allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-grain (WG) diet (150 g/d)
Study: 11703246
Drug: Intravenous PCA
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous PCA
Study: 9104663
Drug: Intramuscular injections
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injections (IM)
Study: 8240927
Drug: (R,S)-atenolol 100
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: (R,S)-atenolol 100 mg
Study: 10335905
Drug: (R)-atenolol 50
Normalized name: atenolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: (R)-atenolol 50 mg
Study: 10335905
Drug: (S)-atenolol 50
Normalized name: atenolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: (S)-atenolol 50 mg
Study: 2946975
Drug: Maprotiline 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maprotiline 150 mg
Study: 2970456
Drug: Zimelidine 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zimelidine 100 mg
Study: 6452797
Drug: Zimelidine 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zimelidine 200 mg
Study: 2946975
Drug: Indalpine 25
Normalized name: Indalpine
DrugBank: Indalpine (DB08953)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indalpine 25 mg
Study: 2946975
Drug: Indalpine 50
Normalized name: Indalpine
DrugBank: Indalpine (DB08953)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indalpine 50 mg
Study: 31640317
Drug: Caffeine mouth
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine mouth rinse (CAF) - 25 ml of mint syrup with 1.2% of CAF, equivalent to 300 mg of CAF
Study: 31640317
Drug: Placebo (PLA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PLA) - 25 ml of mint syrup without CAF
Study: 26329293
Drug: Prednisone (PRD)
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone (PRD) 40 mg/m²/day
Study: 26329293
Drug: Pentoxifylline (PTX)
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline (PTX) 10 mg/kg/day with PRD
Study: 24331154
Drug: Tecemotide (806
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tecemotide (806 μg lipopeptide) administered weekly for 8 weeks, then every 6 weeks until disease progression or withdrawal.
Study: 24331154
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered weekly for 8 weeks, then every 6 weeks until disease progression or withdrawal.
Study: 11777260
Drug: 15 months
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 months of once‐weekly topical amorolfine lacquer + 6 weeks of oral terbinafine (250 mg once daily)
Study: 11777260
Drug: 15 months
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 months of once‐weekly topical amorolfine lacquer + 12 weeks of oral terbinafine (250 mg once daily)
Study: 11777260
Drug: 12 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12 weeks of oral terbinafine (250 mg once daily)
Study: 8510064
Drug: Conservative treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatments including drug therapy and counselling
Study: 16230074
Drug: Entecavir 1.0
Normalized name: ENTECAVIR 1.0 mg ORAL TABLET, FILM COATED [BARACLUDE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entecavir 1.0 mg daily
Study: 18690353
Drug: Clopidogrel (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (600 mg loading dose followed by 75 mg daily) and Aspirin (75-325 mg daily for at least six months)
Study: 9302132
Drug: Alprostadil injections
Normalized name: Alprostadil
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alprostadil injections 3 times per week for 12 weeks
Study: 9302132
Drug: Observation without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Observation without any erectogenic treatment
Study: 9302132
Drug: Alprostadil injections
Normalized name: Alprostadil
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alprostadil injections
Study: 8377686
Drug: Enteric coated
Normalized name: Mesasal Enteric Coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric coated aspirin (100 mg daily)
Study: 2252184
Drug: Diclofenac 75
Normalized name: CAPSAICIN 0.025%/DICLOFENAC 75MG KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 75 mg intramuscularly
Study: 22971253
Drug: Oral health
Normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral health counseling
Study: 27504845
Drug: Oral health
Normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral health counseling and fluoride varnish
Study: 20008946
Drug: Fluoxetine monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine monotherapy (20 mg/day)
Study: 20008946
Drug: Mirtazapine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirtazapine (30 mg/day) plus Fluoxetine (20 mg/day)
Study: 20008946
Drug: Mirtazapine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirtazapine (30 mg/day) plus Venlafaxine (225 mg/day titrated in 14 days)
Study: 20008946
Drug: Mirtazapine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirtazapine (30 mg/day) plus Bupropion (150 mg/day)
Study: 16186422
Drug: Aspirin pretreatment
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin pretreatment (1200 mg PO)
Study: 2459540
Drug: Quinapril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril (10 to 40 mg twice daily, increased every 4 weeks)
Study: 20496731
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of Xinbao pills, 3 pills each time, thrice each day for 4 weeks.
Study: 12759717
Drug: Atropine infusion
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atropine infusion (0.15 microg/kg/min continuously)